Drugs for Gastrointestinal Diseases Practice Questions

Q: What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

All of the above.. The combination of **Magnesium hydroxide** and **Aluminum hydroxide** is the gold standard for non-systemic antacids because it utilizes pharmacological synergy to maximize efficacy while minimizing side effects. ### Why Option D is Correct: 1. **Rapid and Sustained Action:** Magnesium hydroxide is highly soluble and reacts quickly with HCl, providing **rapid relief**. Aluminum hydroxide dissolves slowly, providing a **sustained neutralizing effect** over a longer period. Together, they cover the entire therapeutic window. 2. **Gastric Emptying:** While aluminum ions tend to delay gastric emptying and magnesium ions can accelerate it, the combination has a **neutral effect on gastric motility**, ensuring the antacid remains in the stomach for an optimal duration. 3. **Bowel Movement Balance:** This is the most high-yield clinical point. Magnesium salts cause **osmotic diarrhea**, whereas Aluminum salts cause **constipation** (due to smooth muscle relaxation and phosphate binding). When combined, their opposing effects on the bowel cancel each other out, maintaining normal stool consistency. ### Clinical Pearls for NEET-PG: * **Milk-Alkali Syndrome:** Historically associated with calcium carbonate; characterized by hypercalcemia, metabolic alkalosis, and renal failure. * **Drug Interactions:** Antacids increase gastric pH and can adsorb drugs. They significantly **decrease the absorption** of Tetracyclines, Fluoroquinolones, and Iron. Always advise a 2-hour gap. * **Renal Caution:** Avoid magnesium-containing antacids in patients with **Chronic Kidney Disease (CKD)** due to the risk of hypermagnesemia. * **Phosphate Depletion:** Prolonged use of Aluminum hydroxide can lead to hypophosphatemia (as it binds phosphate in the gut), potentially causing osteomalacia.

Q: What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

All of the above.. The combination of **Magnesium hydroxide** and **Aluminum hydroxide** is a classic pharmacological strategy designed to maximize efficacy while neutralizing individual side effects. ### **Why Option D is Correct:** 1. **Rapid and Sustained Action:** Magnesium hydroxide is highly soluble and reacts quickly with HCl, providing **rapid relief**. Aluminum hydroxide dissolves slowly, providing a **sustained** neutralizing effect. Together, they cover the entire therapeutic window. 2. **Gastric Emptying:** Individual antacids can affect gastric motility; however, the combination has a negligible effect on the rate of gastric emptying compared to single-agent formulations. 3. **Bowel Movement Neutralization:** This is the most high-yield concept. Magnesium salts are osmotic laxatives (causing **diarrhea**), while Aluminum salts are smooth muscle relaxants and astringents (causing **constipation**). When combined, their effects on the bowel cancel each other out, maintaining normal motility. ### **Analysis of Options:** * **Options A, B, and C** are all physiologically accurate benefits of the combination. Since all three contribute to the clinical superiority of the mixture, "All of the above" is the most comprehensive choice. ### **NEET-PG High-Yield Pearls:** * **Systemic vs. Non-systemic:** Both are non-systemic antacids (they do not cause metabolic alkalosis, unlike Sodium Bicarbonate). * **Drug Interactions:** Antacids can chelate other drugs. Remember the mnemonic **"ANTACID"**: Avoid taking with **A**zithromycin/Antibiotics (Tetracyclines/Fluoroquinolones), **N**itrofurantoin, **T**hyroxine, and **I**ron, as they decrease their absorption. * **Renal Failure:** Avoid Magnesium-containing antacids in patients with renal failure to prevent hypermagnesemia (can lead to cardiac arrhythmias and neuromuscular blockade).

Q: The treatment of peptic ulcer involves which of the following classes of drugs?

All of the above. **Explanation:** The treatment of peptic ulcer disease (PUD) focuses on balancing gastric aggressive factors (acid, pepsin) and protective factors (mucus, bicarbonate). The correct answer is **"All of the above"** because each listed class plays a distinct role in reducing gastric acidity. 1. **Antacids (Option A):** These are weak bases (e.g., Aluminum hydroxide, Magnesium hydroxide) that chemically neutralize secreted HCl. They provide rapid symptomatic relief but do not significantly promote ulcer healing on their own. 2. **H2-Receptor Antagonists (Option B):** Drugs like Ranitidine and Famotidine competitively inhibit H2 receptors on parietal cells. They are particularly effective at suppressing **nocturnal acid secretion**, which is largely mediated by histamine. 3. **Proton Pump Inhibitors (Option C):** PPIs (e.g., Omeprazole, Pantoprazole) are the **drugs of choice** for PUD. They irreversibly inhibit the $H^+/K^+$-ATPase pump (the final common pathway of acid secretion), providing superior healing rates compared to H2 blockers. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** PPIs are the mainstay for both gastric and duodenal ulcers. * **H. pylori Eradication:** Most peptic ulcers are associated with *H. pylori*. Triple therapy (PPI + Clarithromycin + Amoxicillin/Metronidazole) is the standard regimen. * **Prostaglandin Analogs:** Misoprostol is specifically used for preventing **NSAID-induced ulcers** but is contraindicated in pregnancy (abortifacient). * **Ulcer Protectives:** Sucralfate requires an **acidic medium** (pH < 4) to polymerize and form a protective paste over the ulcer base; therefore, it should not be given simultaneously with antacids or PPIs.

Q: Which one of the drugs is useful in treating Crohn's disease?

Infliximab. **Explanation:** **Infliximab** is the correct answer because it is a chimeric monoclonal antibody that binds to and neutralizes **Tumor Necrosis Factor-alpha (TNF-α)**, a key pro-inflammatory cytokine in the pathogenesis of Crohn’s disease. It is specifically indicated for inducing and maintaining remission in moderate-to-severe Crohn's disease, especially in patients who are unresponsive to conventional therapy or those with **fistulizing disease**. **Analysis of Incorrect Options:** * **Azathioprine (Option B):** While used as a steroid-sparing maintenance agent in Crohn’s, it is a prodrug of 6-mercaptopurine. It has a slow onset of action (3–6 months) and is generally not used for acute induction or as a primary "curative" biological intervention in the same category as TNF inhibitors. * **Tacrolimus (Option C):** This calcineurin inhibitor is occasionally used for refractory ulcerative colitis or perianal Crohn’s, but it is not a first-line or standard systemic treatment for Crohn’s disease compared to Infliximab. * **Cyclosporine (Option D):** It is highly effective for **acute severe Ulcerative Colitis** (rescue therapy to avoid colectomy) but has shown **minimal to no benefit** in treating Crohn’s disease. **NEET-PG High-Yield Pearls:** * **TNF-α Inhibitors:** Infliximab (chimeric), Adalimumab (fully human), and Certolizumab (pegylated) are all used in Crohn’s. * **Pre-treatment Screening:** Always screen for **Latent Tuberculosis** (via PPD/IGRA) and Hepatitis B before starting Infliximab, as it can cause reactivation. * **Drug of Choice for Fistulizing Crohn’s:** Infliximab. * **Integrin Antagonist:** Vedolizumab is a gut-selective agent used when TNF inhibitors fail.

Q: Which sulfa drug is used in inflammatory bowel disease?

Sulfasalazine. **Explanation** **Sulfasalazine** is the correct answer because it is a prodrug specifically designed to treat Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s disease [1]. It consists of two components linked by a **diazo bond**: **5-Aminosalicylic acid (5-ASA)** and **Sulfapyridine** [1]. * **Mechanism:** The drug remains unabsorbed in the small intestine. Upon reaching the colon, bacterial enzymes (azoreductases) cleave the diazo bond [1]. * **Active Component:** 5-ASA (Mesalamine) acts locally to inhibit prostaglandin and leukotriene synthesis, providing the anti-inflammatory effect [2]. * **Carrier Component:** Sulfapyridine serves only as a carrier to deliver 5-ASA to the colon but is responsible for most of the drug's systemic side effects. **Analysis of Incorrect Options:** * **B. Sulfamethoxazole:** A systemic sulfonamide typically combined with Trimethoprim (Cotrimoxazole) to treat bacterial infections (e.g., UTI, PCP pneumonia). It has no specific role in IBD. * **C. Sulfinpyrazone:** A uricosuric agent used in the management of chronic gout. It inhibits the reabsorption of uric acid in the proximal tubule. * **D. Sulphadoxine:** A long-acting sulfonamide used primarily in combination with Pyrimethamine for the treatment of chloroquine-resistant malaria. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Sulfasalazine commonly causes reversible **oligospermia** and hypersensitivity reactions (due to the sulfa moiety). * **Supplementation:** It inhibits folate absorption; hence, **folic acid supplementation** is mandatory. * **Alternatives:** **Olsalazine** (two 5-ASA molecules) and **Balsalazide** are used in patients intolerant to the sulfa component of sulfasalazine [1], [3].

Q: Which drug is NOT used in the treatment of H. pylori?

Cisapride. **Explanation:** The treatment of *Helicobacter pylori* requires a combination of antibiotics and acid-suppressing agents to eradicate the bacteria and promote ulcer healing. **Why Cisapride is the correct answer:** **Cisapride** is a **prokinetic agent** that acts as a 5-HT₄ receptor agonist. It enhances gastrointestinal motility by increasing acetylcholine release in the myenteric plexus. It is used for conditions like GERD or gastroparesis but has **no antimicrobial activity** and does not affect *H. pylori* colonization. Furthermore, its use is now severely restricted due to the risk of fatal cardiac arrhythmias (Torsades de Pointes) caused by QT interval prolongation. **Why the other options are incorrect:** * **Clarithromycin (Option B):** A macrolide antibiotic that inhibits bacterial protein synthesis. It is a cornerstone of the standard "Triple Therapy" for *H. pylori*. * **Metronidazole (Option C):** An imidazole antibiotic used particularly in patients allergic to penicillin or in areas with low resistance. It is a key component of "Bismuth-based Quadruple Therapy." * **Omeprazole (Option D):** A Proton Pump Inhibitor (PPI). PPIs are essential because they increase gastric pH, which enhances the stability and efficacy of antibiotics like Clarithromycin and Amoxicillin against *H. pylori*. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Triple Therapy (OCM/OCA):** Omeprazole + Clarithromycin + Metronidazole (or Amoxicillin) for 10–14 days. * **Pylera:** A common quadruple therapy regimen containing Bismuth subcitrate, Metronidazole, and Tetracycline. * **Diagnosis:** The **Urea Breath Test** is the non-invasive "gold standard" for confirming eradication. * **Cisapride Warning:** Always remember its association with **CYP3A4 inhibitors** (like Clarithromycin), which can further increase Cisapride levels and exacerbate cardiac toxicity.

Q: Which antiemetic is associated with the following adverse drug reaction?

Dronabinol. ***Dronabinol*** - **Conjunctival injection** (red/bloodshot eyes) is a classic adverse drug reaction of dronabinol, a **synthetic cannabinoid** antiemetic. - Other common side effects include **euphoria**, **dizziness**, and **dry mouth** due to its cannabinoid receptor activity. *Domperidone* - A **dopamine D2 receptor antagonist** that primarily causes **cardiac arrhythmias** and **QT prolongation** as major adverse effects. - Does not cause **conjunctival injection** as it works peripherally and doesn't cross the blood-brain barrier significantly. *Granisetron* - A **5-HT3 receptor antagonist** commonly associated with **headache** and **constipation** as primary adverse effects. - **Conjunctival injection** is not a recognized side effect of this serotonin receptor antagonist. *Aprepitant* - An **NK1 receptor antagonist** that typically causes **fatigue**, **hiccups**, and **decreased appetite** as main adverse reactions. - Does not cause **conjunctival injection** as its mechanism involves neurokinin-1 receptor blockade, not cannabinoid pathways.

Q: Tegaserod acts at which receptor?

Serotonin. **Tegaserod** is a selective **5-HT₄ (Serotonin) receptor partial agonist** [1]. The underlying medical concept involves the "peristaltic reflex" in the gut. When 5-HT₄ receptors on the presynaptic terminals of primary afferent neurons are stimulated, they promote the release of neurotransmitters like acetylcholine and calcitonin gene-related peptide (CGRP). This enhances the propulsion of intestinal contents (prokinetic effect) and increases intestinal secretion [2]. * **Why Serotonin is correct:** Tegaserod specifically targets the 5-HT₄ subtype of serotonin receptors [1]. It was primarily developed to treat Irritable Bowel Syndrome with constipation (IBS-C) and chronic idiopathic constipation in women, as it accelerates gastric emptying and intestinal transit [1]. * **Why Histamine is incorrect:** Histamine receptors in the GI tract (specifically H₂) are targets for drugs like Ranitidine, which inhibit gastric acid secretion. Tegaserod has no affinity for histamine receptors. * **Why Thromboxane is incorrect:** Thromboxane (TXA2) is involved in platelet aggregation and vasoconstriction. Drugs targeting this pathway (like Aspirin or Thromboxane synthase inhibitors) are used in cardiovascular medicine, not as GI prokinetics. **High-Yield Clinical Pearls for NEET-PG:** * **Safety Profile:** Tegaserod was withdrawn from the market (and later restricted) due to an increased risk of **cardiovascular ischemic events** (MI and stroke). * **Other 5-HT₄ Agonists:** Prucalopride (a highly selective agonist used for chronic constipation) and Cisapride/Mosapride (used for GERD and dyspepsia) [1]. * **Mechanism Summary:** 5-HT₄ Agonism → ↑ Acetylcholine release → ↑ Peristalsis [2].

Q: Which of the following drugs is not a component of triple drug therapy for Helicobacter pylori?

Cimetidine. The standard **Triple Drug Therapy** for *Helicobacter pylori* eradication consists of a Proton Pump Inhibitor (PPI) combined with two antibiotics [2]. The goal is to reduce gastric acidity (to allow mucosal healing and enhance antibiotic stability) and eliminate the bacteria. **Why Cimetidine is the correct answer:** Cimetidine is an **H₂-receptor antagonist** [1]. While it reduces acid secretion, it is **not** part of the standard triple therapy regimen [2]. Modern protocols favor PPIs over H₂ blockers because PPIs provide more potent and sustained acid suppression, which is crucial for the efficacy of antibiotics like Clarithromycin and Amoxicillin against *H. pylori* [2]. **Analysis of incorrect options:** * **Lansoprazole (Option A):** This is a PPI [1]. A PPI (e.g., Omeprazole, Lansoprazole, or Rabeprazole) is a mandatory component of triple therapy to maintain a gastric pH > 4 [2]. * **Clarithromycin (Option B):** A macrolide antibiotic that inhibits bacterial protein synthesis. It is the most effective antibiotic against *H. pylori* and is a core component of the regimen. * **Metronidazole (Option C):** An imidazole antibiotic used as an alternative to Amoxicillin, especially in patients with penicillin allergy or in regions with specific resistance patterns. **High-Yield Clinical Pearls for NEET-PG:** 1. **Standard Triple Therapy (7–14 days):** PPI + Clarithromycin (500mg) + Amoxicillin (1g) OR Metronidazole (400mg) twice daily. (Mnemonic: **CAP** – Clarithromycin, Amoxicillin, PPI). 2. **Sequential Therapy:** Involves 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. 3. **Quadruple Therapy:** Used in cases of Clarithromycin resistance. It includes **Bismuth subsalicylate** + PPI + Tetracycline + Metronidazole. 4. **Drug of Choice:** PPIs are the DOC for both *H. pylori* eradication and NSAID-induced ulcers.

Question 1

What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

Accepted Answer

All of the above.

Answer

They possess rapid and sustained acid-neutralizing properties.

Answer

They have less effect on gastric emptying.

Answer

They are less likely to alter bowel movements.

Question 2

What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

Accepted Answer

All of the above.

Answer

They possess rapid and sustained acid-neutralizing properties.

Answer

They have less effect on gastric emptying.

Answer

They are less likely to alter bowel movements.

Question 3

The treatment of peptic ulcer involves which of the following classes of drugs?

Accepted Answer

All of the above

Answer

Antacids

Answer

H2-receptor antagonists

Answer

Proton pump inhibitors

Question 4

Which one of the drugs is useful in treating Crohn's disease?

Accepted Answer

Infliximab

Answer

Azathioprine

Answer

Tacrolimus

Answer

Cyclosporine

Question 5

Despite their short half-lives (2 hours), Proton Pump Inhibitors (PPIs) cause a prolonged suppression of acid secretion (up to 48 hours) because:

Accepted Answer

They irreversibly inhibit the proton pump molecule and hence, acid secretion requires synthesis of new proton pumps.

Answer

They are prodrugs and undergo activation gradually.

Answer

They exit from the plasma and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time.

Answer

They are available as enteric coated capsules, from which drug is gradually released.

Question 6

Which sulfa drug is used in inflammatory bowel disease?

Accepted Answer

Sulfasalazine

Answer

Sulfamethoxazole

Answer

Sulfinpyrazone

Answer

Sulphadoxine

Question 7

Which drug is NOT used in the treatment of H. pylori?

Accepted Answer

Cisapride

Answer

Clarithromycin

Answer

Metronidazole

Answer

Omeprazole

Question 8

Which antiemetic is associated with the following adverse drug reaction?

Accepted Answer

Dronabinol

Answer

Domperidone

Answer

Granisetron

Answer

Aprepitant

Question 9

Tegaserod acts at which receptor?

Accepted Answer

Serotonin

Answer

Histamine

Answer

Thromboxane

Answer

None of the above

Question 10

Which of the following drugs is not a component of triple drug therapy for Helicobacter pylori?

Accepted Answer

Cimetidine

Answer

Lansoprazole

Answer

Clarithromycin

Answer

Metronidazole

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?